Last edition
News about "dersimelagon"
LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.
Dersimelagon | 19/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members